Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results

Durim Delishaj, MD1, Amelia Barcellini, MD2, Romerai D’Amico, MD1, Stefano Ursino, PhD3, Francesco Pasqualetti, PhD3, Ilaria Costanza Fumagalli, MD1, Carlo Pietro Soatti, MD1
1Department of Radiotherapy, Alessandro Manzoni Hospital, Lecco, 2Department of Radiotherapy, National Center of Oncological Hadrontherapy, Pavia, 3Department of Radiotherapy, University Hospital S. Chiara, Pisa, Italy

Abstract

Purpose: To evaluate vaginal toxicity (primary endpoint) and local control (secondary endpoint) in patients with endometrial cancer who underwent primary surgery and adjuvant high-dose-rate (HDR) endovaginal brachytherapy (BT).

Material and methods: In September 2017, the authors conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus, and Cochrane library. In this systematic review, the authors included randomized trials, non-randomized trials, prospective studies, retrospective studies, and cases. The time period of the research included articles published from September 1997 to September 2017.

Results: Acute endovaginal toxicity occurred in less than 20.6% and all acute toxicities were G1-G2. The most common early side effects due to HDR-BT treatment were vaginal inflammation, vaginal irritation, dryness, discharge, soreness, swelling, and fungal infection. G1-G2 late toxicity occurred in less than 27.7%. Finally, G3-G4 late vaginal occurred in less than 2%. The most common late side effects consisted of vaginal discharge, dryness, itching, bleeding, fibrosis, telangiectasias, stenosis, short or narrow vagina, and dyspareunia.

Conclusions: The data suggest that HDR endovaginal brachytherapy, with or without chemotherapy, is very well tolerated with low rates of acute and late vaginal toxicities. Further prospective studies with higher numbers of patients and longer follow-up are necessary to evaluate acute and late toxicities after HDR endovaginal brachytherapy.

Key words: brachytherapy, endometrial cancer, HDR vaginal brachytherapy, radiotherapy.

Purpose

New treatment techniques and early stage diagnoses of endometrial cancer have led to improved cancer-related survivals, with increases in treatment-related adverse sequelae, which often negatively affect patients’ quality of life [1,2]. Surgery, consisting of a total hysterectomy and bilateral salpingo-oophorectomy, with or without lymph node dissection, is the mainstay treatment of endometrial carcinoma [3,4]. As reported in a previous meta-analysis [5], adjuvant external-beam radiotherapy (EBRT) is detrimental in low-risk endometrial cancer (stage IA-IB, grade [G] 1-2, FIGO 1988), it does not affect overall survival (OS) in intermediate-risk disease (stage IC G1-2 or stage IB G3, FIGO 1988), and it provides a significant OS benefit in high-risk disease (stage IC G3, FIGO 1988).

Different studies reported that vaginal brachytherapy (VBT) alone can be used as adjuvant treatment in intermediate-risk disease (stage IB G1-2 disease, stage IA G3 disease, and stage IC G1-2 disease), with very good results in terms of local control and toxicity [6,7,8,9]. The adjuvant treatment should be determined by risk factor assessments such as grading, myometrial invasion, lymphatic vascular space invasion, tumor size, lymph node status, tumor extension to the cervix, and age. In uterine confined disease with deep myometrial invasion, stage IB G3 and stage IC G3, the risk of distant metastases is appreciable despite adjuvant radiotherapy (RT). Adding chemotherapy to adjuvant RT in this subset of patients may improve OS by decreasing distant metastases [10]. Adjuvant intravaginal brachytherapy is often preferred due to very good local control and acceptable acute and late toxicities [11,12,13,14,15]. Therefore, VBT is not without acute and long-term side effects and there are different grading systems for the assessment of clinical vaginal toxicity [16,17,18,19]. Frequently, vaginal side effects are a consequence of damage to the vaginal mucosa, the connective tissues and the small blood vessels. One of the most common acute toxicities is vaginal inflammation, which can be manifested by redness, edema, pain, or an increase in vaginal discharge due to damage to the vaginal mucosa [20,21]. The loss of capillaries and...
impaired microcirculation results in mucosal atrophy, telangiectasias, agglutinations, and easy bleeding. Increased collagen production leads to a loss of elasticity, circumferential fibrosis, and adhesions that can lead to contractions, shortening, narrowing and, in rare cases, complete obliteration of the vagina [22,23,24]. Furthermore, iatrogenic menopause may exacerbate these abnormalities [25,26,27].

Taken together, these adverse vaginal sequelae may increase pain at the time of vaginal examinations, interfere with sexual functioning, be associated with dyspareunia, and negatively affect the patient’s quality of life [28,29]. The aim of this review was to describe acute and late vaginal toxicity (primary endpoint) and local control (secondary endpoint) of patients with low/intermediate-risk endometrial cancer who underwent primary surgery and adjuvant VBT, with or without chemotherapy.

Material and methods

Search strategy

In September 2017, we conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus and Cochrane library. The databases research was made with a combination of following key words: “vaginal brachytherapy”, “toxicity”, and “endometrial cancer” in all fields in databases research. The limit period of research included the articles published from September 1997 to September 2017.

Study selection

In this systematic review, we included randomized trials, non-randomized trials, prospective studies, retrospective studies, and case series of patients affected by endometrial cancer, who underwent surgery treatment and adjuvant vaginal BT. Single case reports and small case series with less than 16 cases were excluded. Moreover, we excluded studies reporting on patients with diagnoses different from endometrial cancer, palliative BT treatment, and interstitial BT treatment. In case of duplicated datasets (e.g., multiple articles from the same study group or institution, related to the same treatment on the same cohort of patient), only the work with the longest follow-up and the greatest number of patients were included.

Data extraction and analysis

Data extraction was performed by one reviewer and checked by a second reviewer. Subsequently, all papers obtained after database research were selected by two reviewers. The first selection was performed by title and abstract reading of each article by each reviewer independently. Then, after the first selection by title and abstract reading, full text of all retrieved papers was reviewed to select suitable articles for the review. After careful selection of articles suitable for the review, we obtained the following information from each report: author identification, year of publication, medical center, study design characteristics, study population, number of patients, age, sex, histological diagnoses, BT technique, total dose, dose for fraction, delivered dose, local control, toxicity, grading scale of toxicity used for each study, and follow-up time. Regarding late and acute toxicities, we considered the study used the following toxicity grading scale: late effects in normal tissues subjective, objective, management and analytic scales (LENT-SOMA) [16], Chassagne [17], late radiation morbidity scoring schema of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) [18], and NCI common terminology criteria for adverse events (CTCAE) [19].

Statistical analysis

Before data performing, an exploration phase of the data was carried out; the categorical data were described by frequency and percentage, whereas continuous data by mean, median, and range. If necessary, after data exploration, analysis and calculation of frequencies, median and range was performed due to description of end points of the review.

All analyses were performed using the Statistical Package for Social Science (SPSS) version 22 software.

Results

The authors’ searches generated a total of 458 results. Through a process of screening, 13 publications were selected for the review. Of 443 reports excluded for this review, 266 were excluded after the first process of screening. After the second process of screening, 168 reports were excluded; 118 reports were excluded because they did not fulfil the inclusion criteria, 67 consisted of reviews, six consisted of conference papers, and one was a book chapter.

Figure 1 shows the flowchart of the systematic literature search process. After the full text review, 11 records were excluded because they did not fulfil the inclusion criteria: different treatment techniques (such as the use of low-dose-rate brachytherapy, interstitial brachytherapy, and external beam radiation therapy with LINAC), number of patients treated, palliative treatment, and diagnoses of endometrial cancer. Therefore, 13 studies fulfilled the inclusion criteria and were included in the review. The characteristics of these studies are summarized in Table 1.

Doses and fractionation

Compared with EBRT, HDR endovaginal BT has some advantages regarding dose distribution. Brachytherapy is a better conformal therapy that allows an improvement of dose delivery to the target and sharpening dose fall-off outside the treatment area [30,31,32,33]. Different studies assessed the dose-effect relationships in vaginal BT [30,31].

In order to evaluate the entire vaginal dose, the Groupe Européen de Curiethérapie and the European Society for Radiotherapy and Oncology (GEC-ESTRO) suggested anatomical reference points as surrogates for the dose distribution along the vaginal axis: one at the mid-vagina (at the level of the posterior-inferior border on the symphysis (PIBS +2 cm), one at the transition from
mid to lower vagina (PIBS), and one at the lower region of the vagina (PIBS –2 cm). PIBS points may contribute to finding dose-effect relationships [30].

The Embrace collaborative group reported that dose to 2 cc (D 2cc ) of the vagina does not correlate with post-radiation vaginal side effects in patients treated with BT for cervical cancer, but an EBRT dose > 45 Gy/25 fractions is a risk factor for vaginal stenosis, and the planning aim of < 65 Gy of 2 Gy equivalent dose (EBRT plus BT dose) to the recto-vaginal reference point is proposed in order to reduce side vaginal effects. In this study, all received EBRT plus BT and the calculation of 2 Gy equivalent dose (EQD2) was performed using the linear-quadratic model with a/b = 10 Gy for tumor and a/b = 3 Gy for late normal tissue damage [30,31].

For these reasons, using BT technique, a high-dose can be given for fractions sparing normal tissue with acceptable acute and late toxicities, as reported through different data in the literature [34,35,36,37,38,40,41,42].

Hypofractionated HDR endovaginal BT regimens, which reduce the number of treatment fractions compared to the conventional regimen (conventional regimen consists delivering a dose of 2 Gy for fraction once a day), have been shown to achieve very good local control without increasing side effects.

Different hypofractionated regimens for the treatment of low/intermediate-risk endometrial cancer have been reported in the literature [9,10,21,22,23,24,25,26,27,28,31,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56]. The most commonly described hypofractionated course consists of a total dose of 21 Gy delivered in three fractions two/three times per week, with very good local control and acceptable acute and late toxicities. For the treatment of vaginal cuff after surgery, the proximal (5 cm) of the vagina was treated. The dose prescription point was at the vaginal surface and at 0.5 cm depth [6,10,11,37,40,41,48,56]. Other authors reported their experiences in the treatment of low/intermediate-risk endometrial cancer using adjuvant HDRBT and different fractionation schedules, such as: 22-24 Gy delivered in six fractions two/three times per week, 18 Gy/three fractions two times per week, 30 Gy/six fractions two/four times per week (Sorbe et al. [8,9]), 34 Gy/four fractions two times per week, 22 Gy/four fractions two/three times per week (Chong et al. [10] and Onsrud et al. [14]), and 20-30 Gy/four fractions one/two times per week (Rios et al. [35]), with similar side effects and local control. Table 1 summarizes the studies with total doses and doses for fraction used for the treatment of low/intermediate-risk endometrial cancer.

**Local control**

Different data in literature reported excellent local control rate in patients with low/intermediate-risk endometrial cancer treated with HDR endovaginal BT. The local control rate is variable reported with a wide range from 87% [Landrum et al. [37] to 93-100% [6,15,23,26,27]. The main factors that may influence local control consist of total dose prescription, doses for fractions, overall treatment time, depth of myometrium invasion, histological type, grading, and lymph vascular infiltration [6,7,8,9,10,11,12,13].

---

**Figure 1.** Flow chart of systematic literature search process
et al. [37] reported a recurrences rate of 13% in 23 patients affected by intermediate-risk endometrial cancer treated with HDR-BT after a median follow-up of 36 months. All patients who experienced relapse had more than one risk factors for endometrial cancer; one patient at histological examination resulted papillary serous carcinoma type and G3, the other patients were stage IIA and G3, third reported myometrium infiltration > 90% and lymphovascular space invasion (LVSI), the last patient with recurrence resulted papillary serous carcinoma type and G3 at histological examination.

The data reported by Qian et al. [27] and Laliscia et al. [56] showed a recurrences rate of 7% after a median follow-up of 18 months and 29 months, respectively. Study of Laliscia et al. [56] included patients with a FIGO stage III (2.4%) unfit to receive EBRT and/or chemotherapy because of comorbidity and age (older than 80 years old); the recurrence rate of patients with FIGO stage > 1C was 18.75%. Finally, the median of local control rate after HDR BT in 10 studies analyzed resulted in 98% (Table 1).

### Acute and late vaginal toxicity

There are few data in the literature concerning acute and late toxicities after endovaginal HDR-BT. As reported in different data in the literature, HDR endovaginal BT is very well tolerated, even using different hypofractionated regimens [34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56]. As shown in Table 2, endovaginal acute toxicity varies widely from 8.7% (Qian et al. [27]) to 20.6% (Laliscia et al. [56]). The respective biologically effective doses {BED ($a/b = 3$)} were 46.7-70 Gy3 and 70 Gy3; calculated EQD2 resulted in 38-42 Gy and 42 Gy, respectively. All acute toxicities were G1-G2 and the most common early side effects due to HDR-BT treatment were vaginal inflammation, vaginal irritation, dryness, discharge, soreness, swelling, and fungal infection [27,56].

Regarding late toxicity (Table 2), the current data in the literature report that the treatment is very well tolerated in patients with low/intermediate-risk endometrial cancer. The main side effects consist of grade G1-G2, with a wide range from 7.5% (Sorbe et al. [9]) to 27.7% (Rios et al. [35]). In the Rios et al. [35] study, the HDR VBT was given after EBRT in 63.8% of patients and the biologically effective prescribed doses were 92 Gy3; the calculated EQD2 resulted in 55.4 Gy. In the Sorbe et al. [9] study, the BED was wide from 15.1 to 56 Gy3 and the calculated EQD2 resulted in < 33.6 Gy.

### Table 1. Summary of studies where high-dose-rate endovaginal brachytherapy was used for the treatment of low/intermediate-risk endometrial cancer

| Study (year) | No of pts | FIGO stage | Age (mean, range) | Dose (Gy) | Fractions | Frequency | Size of cylinder (mm) | LC (%) | Follow-up (median) |
|--------------|-----------|------------|-------------------|-----------|-----------|-----------|----------------------|--------|-------------------|
| Laliscia et al. [56] (2016) | 126 | I-III | 67 (27-90) | 21 | 3 | 2-3/week | 25, 35 | 93 | 29 months |
| MacLeod et al. [7] (1998) | 143 | I-III | 62 (38-90) | 34 | 4 | 2/week | 25, 30, 35, 40 | 96 | 83 months |
| Sorbe et al. [8] (2005) | 290 | I | 64.5 (40-89) | 15, 30 | 6 | 2-4/week | 20, 25, 30 | 98.5 | 60 months |
| Sorbe et al. [9] (2009) | 319 | I | 68 (41-88) | 18, 22, 24 | 3, 6 | 2-3/week | 20, 25, 30 | 98.4 | 60 months |
| Chong et al. [10] (2008) | 173 | I | 64 (36-91) | 22 | 4 | 2-3/week | 20, 23, 26, 30 | 96.5 | 38 months |
| Onsru et al. [14] (2001) | 217 | I-II | 61 (32-85) | 22 | 4 | 5/week | 20, 25, 30, 35, 40 | 99 | 84 months |
| Qian et al. [27] (2017) | 375 | I-II | 65 (43-94) | 14, 18, 21 | 2, 3 | 2-3/week | 20, 23, 26, 30 | 93 | 18 months |
| Greven et al. [34] (2004) | 46 | I-II | – | 18 | 3 | 2-3/week | – | 97 | 29 months |
| Rios et al. [35] (2015) | 154 | I-III | 69 (39-90) | 10, 20 | 2, 4 | 2-3/week | 20, 25, 30, 35 | 97.9 | 47 months |
| De Boer et al. [36] (2015) | 213 | I-II | 69 (46-89) | 21 | 3 | – | – | 97.5 | 84 months |
| Landrum et al. [37] (2014) | 23 | I-II | 69 (46-81) | 21 | 3 | 3/week | – | 87 | 36 months |
| Rovirosa et al. [38] (2012) | 112 | I-III | 66 (39-90) | 10, 20, 30 | 2, 4 | 1-2/week | – | 100 | 30 months |
| Nout et al. [6] (2010) | 213 | I-II | 70 | 21 | 3 | 2-3/week | – | 100 | 45 months |

FIGO – International Federation of Gynecology and Obstetrics; LC – local control
The most common late G1-G2 side effects reported consisted of vaginal discharge, dryness, itching, bleeding, fibrosis, telangiectasias, stenosis, short or narrow vagina, and dyspareunia.

G3-G4 late vaginal toxicities have been reported only in a few cases (four studies) and resulted in less than 2% of cases (Nout et al. PORTEC-2 study [6]), consisting of slight atrophy, bleeding, and stenosis [6]. Table 2 describes the summary of acute and late vaginal toxicity after endovaginal HDR brachytherapy.

### Table 2. Summary of acute and late vaginal toxicities after high-dose-rate endovaginal brachytherapy in patients with low/intermediate-risk endometrial cancer

| Author (year) | Acute vaginal toxicity | Late vaginal toxicity | Score used |
|--------------|------------------------|-----------------------|------------|
| Laliscia et al. [56] (2016) | 20.6 0 Vaginal inflammation Dyspareunia | 23 0 Fibrosis Telangiectasias Dryness Stenosis | CTCAE v. 4.2 |
| MacLeod et al. [7] (1998) | – – – | 15.4 0 Discharge | RTOG/EORTC |
| Sorbe et al. [8] (2005) | – – – | 24.6 0 Vaginal discharge Dryness Itching Discharge Bleeding | – |
| Sorbe et al. [9] (2009) | – – – | 7.5 < 1 Slight atrophy Bleedings Fibrosis Stenosis | – |
| Chong et al. [10] (2008) | – – – | 12.7 0 Stenosis Bleeding | CTCAE v. 3.0 |
| Onsrud et al. [14] (2001) | – – – | 24.4 0 Stenosis | Chassagne |
| Qian et al. [27] (2017) | 15.8 0 Vaginal irritation Dryness Discharge Soreness Swelling Fungal infection | 13.6 0 Stenosis | CTCAE v. 4.0 |
| Greven et al. [34] (2004) | 11.5 – – | 26.1 – – | RTOG/EORTC |
| Rios et al. [35] (2015) | 8.7 0 – | 27.7 0.07 – | LENT-SOMA |
| De Boer et al. [36] (2015) | – – – | 23.4 0 Dryness Short or narrow vagina | EORTC QLQ-C30 |
| Landrum et al. [37] (2014) | – – – | 13.1 – Dyspareunia Stenosis Dryness | CTCAE v. 3.0 |
| Rovirosa et al. [38] (2012) | 10.9 0 – | 24.9 0.09 Stenosis | RTOG/EORTC |
| Nout et al. [6] (2010) | 25.2 0 – – 2 Atrophy Stenosis Shortening or narrowing | EORTC-RTOG |

RTOG – Radiation Therapy Oncology Group; NCI – National Cancer Institute; CTCAE – common terminology criteria for adverse events; EORTC – European Organization for Research and Treatment of Cancer; LENT – late effects normal tissue task force; SOMA – subjective, objective, management, analytic scale

**Discussion**

Laparotomy, peritoneal washing, total extra-fascial hysterectomy, and bilateral salpingo-oophorectomy with or without pelvic ± aortic lymphadenectomy is the stan-
dard treatment for endometrial cancer [2,3,4]. Adjuvant RT, with or without chemotherapy, is often indicated in patients after complete surgical staging. Risk factors such as grading, myometrial invasion, lymphatic vascular space invasion, tumor size, lymph node status, tumor extension to the cervix, and age should be considered for adjuvant treatment of endometrial cancer. In patients with uterine confined disease and deeply myometrial invasion, stage IB G3 and stage IC G3, adding chemotherapy to adjuvant RT may improve the OS [5,6,7,8,9,10,11,12,13,14,15,57,58,59,60].

The Postoperative Radiation Therapy in Endometrial Cancer (PORTEC 2) [6] trial randomly allocated 427 patients with intermediate/high-risk endometrial cancer to receive either adjuvant vaginal BT (21 Gy with high-dose-rate [HDR] or 30 Gy with low-dose-rate [LDR]), or adjuvant pelvic EBRT (46 Gy) [8,9]. The two arms had similar 3-year vaginal recurrence rates (0.9% for vaginal BT vs. 2% for EBRT) and 5-year OS rates (90.4% vs. 90.8%), whereas patients enrolled into vaginal BT arm experienced better social functioning, less bowel toxicity, and better quality of life (QOL). In vaginal BT arm, G3-G4 late vaginal toxicities resulted in less than 2% and consisted of slight atrophy, bleedings, and stenosis.

HDR VBT alone is often preferred as adjuvant therapy in patients with intermediate-risk endometrial cancer due to excellent local control and low-rate of acute and late toxicities [6,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,60]. However, there is a lack of data in literature concerning acute and late toxicities after HDR vaginal BT as exclusive post-operative radiotherapy.

Different data in literature showed one correlation between total dose prescribed, doses for fractions, length of vagina treated, and vaginal late toxicity [8,48,49,50,51,52,53,54,55,56,60,61,62,63,64,65]. Sorbe et al. [8] in 2005 reported results of a randomized study using two different dose-per-fraction in patients with IA-IB stage endometrial cancer treated with endovaginal HDR brachytherapy. Overall, 290 patients were treated vaginal applicators with diameters of 20-30 mm. The dose per fraction prescribed was randomly set to 2.5 Gy (total dose of 15.0 Gy) or 5.0 Gy (total dose of 30.0 Gy). One hundred forty-four patients were treated with 2.5-Gy fraction and 146 5.0-Gy fractions. The dose prescription was at 5 mm depth from the surface of the vaginal cylinder using the HDR technique. The overall locoregional recurrence rate was 1.4% and the rate of vaginal recurrences 0.7%. There was no difference between the two randomized groups. The vaginal shortening, mucosal atrophy, and bleedings were highly significant ($p < 0.000001$) in the 5.0-Gy group after 5 years.

In Park et al. study [43], predictors of vaginal stenosis after intravaginal HDR brachytherapy in endometrial carcinoma were analyzed. After a median follow-up of 12.9 months, all 101 patients analyzed were disease-free. Highest vaginal stenosis (VS) grades were zero in 67%, one in 26%, two in 6%, and three in 1%. Multivariable analysis revealed that proportion of vagina treated > 60% (odds ratio [OR]: 3.48; $p = 0.009$) and total dose > 14 Gy (OR: 4.27; $p = 0.015$) were independent predictors of grade ≥ 1 vaginal stenosis (VS), and lack of consistent dilator use was an independent predictor of grade ≥ 2 VS (OR: 5.60; $p = 0.047$). Authors concluded that higher total dose to a larger proportion of the vagina were more likely to develop grade ≥ 1 vaginal stenosis.

MacLeod et al. [7] used HDR vaginal BT only (34 Gy in four fractions prescribed to vaginal mucosa in a two-week period) in 143 patients. Five-year disease-free survival (DFS) and five-year OS were 100% and 88% for stage IA (FIGO 1988), 98% and 94% for stage IB, 100% and 86% for stage IC, and 92% and 92% for stage IIA, respectively. The overall vaginal recurrence rate was 1.4%, and the overall late-toxicity rate was low, with no grade ≥ 3 toxicities. The vaginal toxicity (grade 1 and 2) was reported in 15.4% of patients.

Different authors reported that the local treatment appears to reduce vaginal atrophy and related symptoms in women treated with radiotherapy for gynecological cancers. This local therapy may favor regeneration and epithelial proliferation, and improve vaginal trophism, elasticity, and adequate lubrication. Finally, the consistent dilator use may also be protective against grade ≥ 2 of vaginal stenosis [48,54,55,56,60].

The limitations of the present review are due to the lack of data in the literature regarding the study of late and acute vaginal toxicities after adjuvant intravaginal HDR BT. Many of the studies analyzed were retrospective, and acute and late toxicity was not described in detail. Further, the studies were performed in different countries using different grading scale, dose prescription, and doses per fraction.

Conclusions

There is a lack of data in the literature regarding the incidence and preventative strategies of vaginal toxicity after adjuvant HDR endovaginal BT. The authors’ data suggest that HDR adjuvant endovaginal BT (with or without chemotherapy) is very well tolerated with very good local control disease in low/intermediate-risk endometrial cancer. Patients with high-risk disease (stage IC, G3, or clear cell histology) should be considered for more extensive treatment. Further prospective studies with a higher number of patients and longer follow-up to evaluate acute and late toxicities after endovaginal HDR BT are recommended.

Disclosure

Authors report no conflict of interest.
References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
2. Nout RA, Putter H, Jürgenliemk-Schultz IM et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27: 3547-3556.
3. Cowles TA, Magrina JF, Masterson BJ, Capen CV. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 1985; 66: 413-416.
4. Burke WM, Orr J, Leitao M et al. SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014; 134: 385-392.
5. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007; 114: 1313-1320.
6. Nout R, Smit V, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823.
7. MacLeod C, Fowler A, Duval P et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys 1998; 42: 1033-1039.
8. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for Stage I endometrial cancer: A randomized study of two dose-per-fraction levels. Int J Radiat Oncol Biol Phys 2005; 62: 1385-1389.
9. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for Stage I endometrial cancer: A randomized study of two dose-per-fraction levels. Int J Gynecol Cancer 2009; 19: 873-878.
10. Chong I, Hoskin PJ. Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. Brachytherapy 2008; 7: 195-199.
11. Colombo N, Creutzberg C, Amant F et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiother Oncol 2015; 117: 559-581.
12. Alektiar KM, McKee A, Venkatraman E et al. Intravaginal high dose rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys 2002; 53: 707-713.
13. Anderson JM, Stea B, Hallum AV et al. High-dose-rate postoperative vaginal cuff irradiation alone for Stage IB, and IC endometrial cancer. Int J Radiat Oncol Biol Phys 2000; 46: 417-425.
14. Onsrud M, Strickert T, Mathiesen AB. Late reactions after postoperative high-dose-rate intravaginal brachytherapy for endometrial cancer: a comparison of standardized and individualized target volumes. Int J Radiat Oncol Biol Phys 2001; 49: 749-755.
15. Lin LL, Mutch DG, Rader JS et al. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol 2007; 106: 215-220.
16. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995; 31: 1049-1091.
17. Chassagne D, Sismondi P, Horiot JC et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 1993; 26: 195-202.
18. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
19. CTCAE v. 4.0. NIH Publication No. 09-5410.
20. Katz A, Njiguena E, Rakowsky E et al. Early development of vaginal shortening during radiation therapy for endometrial or cervical cancer. Int J Gynecol Cancer 2001; 11: 234-235.
21. Abitbol MM, Davenport JH. The irradiated vagina. Obstet Gynecol 1974; 44: 249-256.
22. Grigsby FW, Russell A, Bruner D et al. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol Biol Phys 1995; 31: 1281-1299.
23. Brand AH, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2006; 16: 288-293.
24. Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol 1999; 11: 46-48.
25. Jackson S, James M, Abrams P. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 2002; 109: 339-344.
26. Pitkin RM, Bradbury JT. The effects of topical estrogen on irradiated vaginal epithelium. Am J Obstet Gynecol 1965; 15: 175-182.
27. Qian JM, Stahl JM, Young MR et al. Impact of vaginal cylinder diameter on outcomes following brachytherapy at for early stage endometrial cancer. J Radiol Oncol Biol Phys 2017; 28: 874.
28. Wolf JK. Prevention and treatment of vaginal stenosis resulting from pelvic radiation therapy. Commun Oncol 2006; 3: 665-671.
29. Bertelson K. Sexual dysfunction after treatment of cervical cancer. Danish Med Bull 1985; 30: 31-34.
30. Kirchheiner K, Nout RA, Tanderup K et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo) therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys 2013; 89: 88-95.
31. Oyekunle EO, Obed RI, Akinlade B, Ntekim A. Comparison of doses to the rectum derived from treatment planning system with in-vivo dose values in vaginal vault brachytherapy using cylinder applicators. J Contemp Brachytherap 2015; 7: 485-491.
32. Hassouna A, Bahadur YA, Constantinescu C et al. Assessment of air pockets in high-dose-rate vaginal cuff brachytherapy using cylindrical applicators. J Contemp Brachytherap 2014; 6: 271-275.
33. Kirchheiner K, Nout RA, Lindegaard JC et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo) therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol 2016; 118: 160-166.
34. Greven K, Winter K, Underhill K et al. Radiation Therapy Oncology Group. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2004; 59: 168-173.
35. Rios I, Rovirosa A, Ascaso C et al. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients. Clin Transl Oncol 2016; 18: 925-930.
36. De Boer SM, Nout RA, Jürgenliemk-Schultz IM et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 Trial. Int J Radiat Oncol Biol Phys 2015; 93: 797-809.
37. Landrum LM, Nugent EK, Zuna RE et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol 2014; 132: 50-54.
38. Rovirosa A, Valduvieco I, Ascaso C et al. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma. Clin Transl Oncol 2013; 15: 111-116.

39. Hong JJ, Yacoub SF, Elekans JC et al. El-Mahdi AM. High dose rate vaginal brachytherapy in early stage endometrial carcinoma: preliminary analysis. Am J Clin Oncol 1997; 20: 254-258.

40. Weiss E, Hirnle P, Arnold-Bofinger H et al. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy. Gynecol Oncol 1998; 71: 72-76.

41. Chada M, Nanavati PJ, Liu P et al. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 1999; 75: 103-107.

42. Horowitz NS, Peters WA, Smith MR et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol 2002; 99: 235-240.

43. Park HS, Ratner ES, Lucarelli I et al. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015; 14: 464-470.

44. Damast S, Higgins S, Ratner E et al. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. J Contemp Brachytherapy 2015; 7: 35-40.

45. Eldredge-Hindy HB, Eastwick G, Anne PR et al. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy 2014; 6: 262-270.

46. Eltabbakh, GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys 1997; 38: 373-380.

47. Nunns D, Williamson K, Swaney L, Davy M. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J Gynecol Cancer 2000; 10: 233-238.

48. Fanning J, Nanavati PJ, Hilgers RD et al. Surgical staging and high dose rate brachytherapy for endometrial cancer: limiting external radiotherapy to node-positive tumors. Obstet Gynecol 1996; 87: 1041-1044.

49. Kellas-Słęczka S, Wojcieszek P, Bialas B et al. Adjuvant vaginal brachytherapy as a part of management in early endometrial cancer. J Contemp Brachytherapy 2012; 4: 247-252.

50. Schover LR, Fife M, Gershenson DM et al. Sexual dysfunction and treatment for early stage cervical cancer. Cancer 2006; 63: 204-212.

51. Laliscia C, Fabrini MG, Delishaj D et al. Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer. Int J Gynecol Cancer 2017; 27: 396-402.

52. Laliscia C, Fabrini MG, Delishaj D et al. Concomitant external-beam irradiation and chemotherapy followed by high-dose rate brachytherapy boost in the treatment of squamous cell carcinoma of the vagina: a single-center retrospective study. Anticancer Res 2016; 36: 1885-1889.

53. Gerdin B, Hallgren R. Dynamic role of hyaluronan (HYA) in connective tissue activation and inflammation. J Intern Med 1997; 242: 49-55.

54. Markowska J, Madry R, Markowska A et al. The effect of hyaluronic acid (Cicatridine) on healing and regeneration of the uterine cervix and vagina and vulvar dystrophy therapy. Eur J Gynaecol Oncol 2011; 32: 65-68.

55. Dinicola S, Pasta V, Costantino D et al. Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy. Minerva Ginecol 2015; 67: 523-531.

56. Laliscia C, Delishaj D, Fabrini MG et al. Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? J Contemp Brachytherapy 2016; 8: 512-517.

57. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106: 413-425.